MFA Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

MFA Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-238	Closed	-$12.5K	–	160
2020 Q2	$12.5K	Buy	+238	New	+$9.95K	0.01%	146

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

MFA Wealth Advisors's PCRX Position: Q3 2020 in Review

MFA Wealth Advisors sold out of Pacira BioSciences (PCRX) in Q3 2020, closing a stake of 238 shares — an estimated $12.5K sold.

MFA Wealth Advisors first reported a position in PCRX in Q2 2020 and held it in 1 quarter. The position peaked at $12.5K in Q2 2020. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

MFA Wealth Advisors reported no remaining Pacira BioSciences position as of Q3 2020 after selling out during the quarter.
MFA Wealth Advisors sold 238 Pacira BioSciences shares in Q3 2020, an estimated $12.5K.
MFA Wealth Advisors first reported a position in Pacira BioSciences in Q2 2020 and held it in 1 quarter.
MFA Wealth Advisors's Pacira BioSciences position peaked at $12.5K in Q2 2020.
257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on MFA Wealth Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.